Vistagen Shares Rise After Positive Phase 3 Extension Data for Fasedienol Nasal Spray

Vistagen Therapeutics (VTGN) reported preliminary data on September 22, 2026, from the open-label extension portion of its PALISADE-4 Phase 3 study of fasedienol nasal spray for acute treatment of social anxiety disorder. The company's stock moved higher following the announcement. The OLE phase follows the completion of the double-blind portion of PALISADE-4, designed to assess longer-term safety and tolerability of fasedienol in patients with social anxiety disorder. Vistagen did not disclose detailed efficacy or safety figures in the preliminary report. Fasedienol is an investigational pherine nasal spray intended as an acute, as-needed treatment for social anxiety disorder, a condition affecting an estimated 15 million U.S. adults. Shares of VTGN rose on the news.